Keep in mind that most on this board spewing nonsense about Zalicus don't have a pot to #$%$ in but they feel empowered to rip companies they know nothing about nor do they have much $$ in the game - this is a board for comedic relief and nothing more so don't get too wrapped up in the ignorance. Zalicus will be at $3 again or higher in 2013 and voting for the R/S does make sense. I had a lengthy conversation with Justin and was so impressed -- were in good hands but it's the bio industry -- risky. Long and Bullish.
I agree. I keep buying more. Sure it is risky but I believe Novratis will renew the partnership and Z160 will have good results. How do I know? I don't. All stock trading is a gamble. This just happens to be a riskier gamble with higher potential.
Perhaps but it's an R&D run company and they probably need some more balance on the marketing specialist side. You just can't stick your head in a hole and think that people will hear you. The research is good but they need someone to clarify to the market the monetization model. Building partnerships and revenue streams, possibly exploring buyout opportunities. What is the exit strategy besides selling the stock out?
You are absolutely right! Especially after failure of Synavive and suspended Prednisporin. And this Z160 was returned from Merck. They need to go out to let the investors know this new improved Z160. And Z944 should have some positive news come out to let investors not hesitate on investing!
I was loaded before I started buying shares of ZLCS. LOL. I had been wanting a bad habit for years. Some guys use drugs, gamble, or mistresses; I have ZLCS to help me spend my hard(sort of) earned money. 2012 and 1Q of 2013 has been tough for ZBA members.